+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANKL inhibition as therapy for joint damage

RANKL inhibition as therapy for joint damage

Nihon Rinsho Men'eki Gakkai Kaishi 30(5): 404-407

RANK ligand (RANKL) is a key mediator of osteoclast formation, function, and survival. Therefore, RANKL is thought to be responsible for osteoclast-mediated bone resorption in a broad range of disorders such as postmenopausal osteoporosis and cancer-induced bone disease. Moreover, RANKL has been implicated as a primary mediator of bone erosions, a hallmark of rheumatoid arthritis (RA). Denosumab is a fully human monoclonal antibody. This antibody binds to RANKL with high affinity and specificity, and inhibits RANKL-RANK interaction, mimicking the endogenous effects of osteoprotegerin (OPG), a soluble RANKL decoy receptor. Clinical trial data support the continued development of denosumab for the inhibition of bone erosions in RA.

(PDF emailed within 1 workday: $29.90)

Accession: 055333173

Download citation: RISBibTeXText

PMID: 17984581

Related references

JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis and Rheumatism 64(11): 3531-3542, 2013

Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice: a new therapy for human RANKL-dependent ARO. Journal of Bone and Mineral Research 27(12): 2501-2510, 2013

Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling. Journal of Cellular Physiology 221(3): 572-578, 2009

Discovery of osteoclast differentiation factor, RANKL Inhibition of bone resorption by blocking RANKL-RANK signaling. Japanese Journal of Pharmacology 88(Supplement 1): 17P, 2002

Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice. Modern Rheumatology 25(1): 50-55, 2015

Reflex inhibition of muscle in patients with joint damage. British Journal of Rheumatology 25(SUPPL), 1986

Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. Arthritis and Rheumatism 44(10): 2242-2246, 2001

Irreversible inhibition of RANK expression as a possible mechanism for IL-3 inhibition of RANKL-induced osteoclastogenesis. Biochemical and Biophysical Research Communications 399(4): 688-693, 2010

Inhibition of P2X4 suppresses joint inflammation and damage in collagen-induced arthritis. Inflammation 37(1): 146-153, 2014

Damage due to overuse of the knee joint-surgical therapy. Der Orthopade 9(3): 198-200, 1980

Surgical therapy for cartilage damage of the knee joint. Zeitschrift für Orthopadie und Ihre Grenzgebiete 143(5): R83-95; Quiz R96-9, 2005

Induction of osteoarthritis in the rat by surgical tear of the meniscus: Inhibition of joint damage by a matrix metalloproteinase inhibitor. Osteoarthritis and Cartilage 10(10): 785-791, 2002

Preventing joint damage as the best measure of biologic drug therapy. Journal of Rheumatology. Supplement 65: 39-43, 2002

Progressive joint damage during penicillamine therapy for rheumatoid arthritis. Clinical Rheumatology 6(1): 122-123, 1987

RANKL as a target molecule for treatment of joint destruction. Clinical Calcium 17(4): 586-592, 2007